Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus DUO MEDIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus DUO MEDIHALER.
DICYCLOMINE HYDROCHLORIDE vs DUO-MEDIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Combination of fluticasone propionate, a corticosteroid with anti-inflammatory activity, and salmeterol, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
10-20 mg orally 3-4 times daily
Two inhalations (50 mcg ipratropium bromide and 100 mcg fenoterol hydrobromide per inhalation) four times daily via metered-dose inhaler.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life of 3-4 hours for the bronchodilator component and 6-8 hours for the corticosteroid component; clinically requires twice-daily dosing.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Renal: 70-80% (free drug and metabolites), Biliary/Fecal: 10-20%
Category A/B
Category C
Anticholinergic
Anticholinergic/Beta2-Agonist Combination